Opioid

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.

Purdue pain drug gets priority status

Purdue pain drug gets priority status

By

Purdue Pharma expects the FDA to vote yea or nay on the drug by October.

Zohydro's second act

Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.

Study: Opioid deaths outnumber heroin-associated ones

Study: Opioid deaths outnumber heroin-associated ones

By

Researchers at Montreal's McGill University survey the explosion in prescription painkiller use and abuse.

Top opioid prescribers not pain specialists

Express Scripts said that family and internal medicine doctors were the top opioid prescribers between 2011 and 2012.

Chicago sues painkiller companies

The Windy City seeks $9.5 million in damages in a lawsuit that accuses manufacturers of misleading consumers.

CA counties sue makers of painkillers

Orange and Santa Clara counties are suing painkiller makers like Purdue and Endo, a suit akin to deceptive ad cases launched against the tobacco industry.

New painkillers stalk Zohydro

New painkillers stalk Zohydro

By

Two drugmakers, Purdue Pharma and Teva, have abuse-deterrent hydrocodone medications either under FDA review or in late-stage testing.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Massachusetts bans Zohydro

The Bay State is saying no to the controversial prescription painkiller.

Senator seeks anti-Zohydro legislation

West Virginia's Joe Manchin has sponsored a bill to push pain medication Zohydro off the FDA's approval list.

Possible Zohydro competitor surfaces

Possible Zohydro competitor surfaces

By

A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.

Email Newsletters